TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

About The Tribune-Review
The Tribune-Review can be reached via e-mail or at 412-321-6460.
Contact Us | Video | Photo Reprints

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY


By Bloomberg News

Published: Tuesday, June 18, 2013, 12:01 a.m.

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Emboldened by Italy move, QVC to expand into France
  2. NBA player plans Russia’s 1st Hooters
  3. Wages have soared in Pittsburgh, but economy appears to have stalled
  4. PPG shareholders vote against proposals; sales, profit see double-digit increases
  5. Earnings carry more weight as investors attempt to look past winter
  6. Consol Energy transitions as leadership changes hands
  7. How’s your doctor doing? Comparison shop online
  8. Region’s largest bank PNC posts 7% rise in 1Q profit
Subscribe today! Click here for our subscription offers.